Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pasithea Therapeutics Corp (KTTA)

Pasithea Therapeutics Corp (KTTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,331
  • Shares Outstanding, K 1,266
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,960 K
  • EBIT $ -16 M
  • EBITDA $ -15 M
  • 60-Month Beta 0.73
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.16

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.37 +10.97%
on 12/19/24
3.32 -20.78%
on 11/21/24
-0.56 (-17.55%)
since 11/20/24
3-Month
2.37 +10.97%
on 12/19/24
7.50 -64.93%
on 09/26/24
-1.79 (-40.50%)
since 09/20/24
52-Week
2.37 +10.97%
on 12/19/24
9.40 -72.02%
on 12/26/23
-2.97 (-53.04%)
since 12/20/23

Most Recent Stories

More News
Pasithea Therapeutics Advances PAS-004 Clinical Trial to Next Dose Level Following Positive Safety Review Findings

Pasithea Therapeutics advances PAS-004 trial to 15mg, noting no dose-limiting toxicities or rashes in initial patients.Quiver AI SummaryPasithea Therapeutics Corp. has received a recommendation from its...

KTTA : 2.63 (-1.50%)
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

KTTA : 2.63 (-1.50%)
KTTAW : 0.0230 (-8.00%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END

KTTA : 2.63 (-1.50%)
DAWN : 12.79 (+2.65%)
SWTX : 35.59 (+2.33%)
VSTM : 4.19 (-5.63%)
KNTE : 2.65 (-0.38%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

/PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue....

KTTA : 2.63 (-1.50%)
SWTX : 35.59 (+2.33%)
DAWN : 12.79 (+2.65%)
VSTM : 4.19 (-5.63%)
KNTE : 2.65 (-0.38%)
Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the “Investor Group” or “we”), who are collectively the largest...

KTTA : 2.63 (-1.50%)
Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the “Investor Group” or “we”), who are collectively the largest...

KTTA : 2.63 (-1.50%)
Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics

Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who are collectively the largest stockholder...

KTTA : 2.63 (-1.50%)
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028

Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide...

KTTA : 2.63 (-1.50%)
AZN : 65.35 (+1.41%)
LOGC : 6.73 (+1.51%)
CRDF : 4.26 (-5.12%)
SWTX : 35.59 (+2.33%)
DAWN : 12.79 (+2.65%)
Investor Group Sends Letter to Pasithea Therapeutics’ Board of Directors

Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who are collectively the largest stockholder...

KTTA : 2.63 (-1.50%)
Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics

Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who together are one of the largest stockholders...

KTTA : 2.63 (-1.50%)

Business Summary

Pasithea Therapeutics Corp. is a biotechnology company. It focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Pasithea Therapeutics Corp. is based in MIAMI BEACH, Fla.

See More

Key Turning Points

3rd Resistance Point 3.00
2nd Resistance Point 2.90
1st Resistance Point 2.77
Last Price 2.63
1st Support Level 2.54
2nd Support Level 2.44
3rd Support Level 2.30

See More

52-Week High 9.40
Fibonacci 61.8% 6.71
Fibonacci 50% 5.88
Fibonacci 38.2% 5.06
Last Price 2.63
52-Week Low 2.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar